Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
Tomas KalincikIbrahima DioufSifat SharminCharles MalpasTim SpelmanDana HorakovaEva Kubala HavrdovaMaria TrojanoGuillermo IzquierdoAlessandra LugaresiAlexandre PratMarc GirardPierre DuquettePierre GrammondVilija JokubaitisAnneke van der WaltFrancois Grand'MaisonPatrizia SolaDiana FerraroVahid ShaygannejadRaed AlroughaniRaymond HuppertsMurat TerziCavit BozJeannette Lechner-ScottEugenio PucciVincent Van PeschFranco GranellaRoberto BergamaschiDaniele SpitaleriMark SleeSteve VucicRadek AmpapaPamela McCombeCristina Ramo-TelloJulie PrevostJavier OlascoagaEdgardo CristianoMichael BarnettMaria Laura SaladinoJose Luis Sanchez-MenoyoSuzanne HodgkinsonCsilla RozsaStella HughesFraser MooreCameron ShawErnest ButlerOlga SkibinaOrla GrayAllan KermodeTunde CsepanyBhim SinghalNeil ShueyImre PiroskaBruce TaylorMagdolna SimoCarmen-Adella SirbuAttila SasHelmut Butzkuevennull nullPublished in: Neurology (2020)
This study provides Class IV evidence that, for patients with relapsing-remitting MS, long-term exposure to immunotherapy prevents neurologic disability.